Design of a post-market registry for the extravascular implantable cardioverter-defibrillator: The Enlighten Study

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Heart Rhythm O2 Pub Date : 2025-01-01 DOI:10.1016/j.hroo.2024.09.022

Lucas V.A. Boersma MD, PhD , Anish Amin MD , Nicolas Clémenty MD, PhD , David Duncker MD , Gregory Engel MD , Laurence Epstein MD , Vikas Kuriachan MD , Camille Frazier-Mills MD , Marianne Gwechenberger MD , Nobuhiro Nishii MD , Jeff Lande PhD , Christopher Wiggenhorn PhD , Ian Crozier MB ChB

{"title":"Design of a post-market registry for the extravascular implantable cardioverter-defibrillator: The Enlighten Study","authors":"Lucas V.A. Boersma MD, PhD , Anish Amin MD , Nicolas Clémenty MD, PhD , David Duncker MD , Gregory Engel MD , Laurence Epstein MD , Vikas Kuriachan MD , Camille Frazier-Mills MD , Marianne Gwechenberger MD , Nobuhiro Nishii MD , Jeff Lande PhD , Christopher Wiggenhorn PhD , Ian Crozier MB ChB","doi":"10.1016/j.hroo.2024.09.022","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The extravascular implantable cardioverter-defibrillator (EV-ICD) with substernal lead placement has been shown to terminate ventricular arrhythmias safely and effectively while being outside the vasculature. The performance of the EV-ICD system with a novel inappropriate shock-reducing algorithm in a real-world setting has yet to be investigated.</div></div><div><h3>Objective</h3><div>The objective of the Enlighten Study: the EV-ICD Post-Approval Registry is to provide a comprehensive measure of the safety and performance of the EV-ICD system in real-world clinical practice over the lifetime of the device.</div></div><div><h3>Methods</h3><div>The Enlighten Study is a global, prospective, observational, multicenter, post-approval study utilizing the manufacturer’s Product Surveillance Registry. Eligible patients implanted with an Aurora EV-ICD system at participating centers will be included. Follow-up clinical data will be collected approximately every 6 months throughout the lifetime of the device, enrolling a minimum of 500 patients.</div></div><div><h3>Results</h3><div>The primary endpoint of the study is major system-related complication-free survival at 5 years post-implantation, with a minimum threshold of >79%. The study will also characterize device performance that includes, but is not limited to, freedom from system- or procedure-related complications, performance of antitachycardia pacing, characterization of sensing and detection, inappropriate therapy, shock effectiveness, battery depletion, and system revisions.</div></div><div><h3>Conclusion</h3><div>The Enlighten Study: the EV-ICD Post-Approval Registry will examine the real-world performance of the post-market EV-ICD system. Additionally, this study will allow for a robust assessment of EV-ICD–related complications, device revisions, and extractions over chronic (>5 years) implant durations.</div></div><div><h3>ClinicalTrials.gov ID</h3><div><span><span>NCT06048731</span><svg><path></path></svg></span></div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"6 1","pages":"Pages 64-69"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart Rhythm O2","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666501824003271","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The extravascular implantable cardioverter-defibrillator (EV-ICD) with substernal lead placement has been shown to terminate ventricular arrhythmias safely and effectively while being outside the vasculature. The performance of the EV-ICD system with a novel inappropriate shock-reducing algorithm in a real-world setting has yet to be investigated.

Objective

The objective of the Enlighten Study: the EV-ICD Post-Approval Registry is to provide a comprehensive measure of the safety and performance of the EV-ICD system in real-world clinical practice over the lifetime of the device.

Methods

The Enlighten Study is a global, prospective, observational, multicenter, post-approval study utilizing the manufacturer’s Product Surveillance Registry. Eligible patients implanted with an Aurora EV-ICD system at participating centers will be included. Follow-up clinical data will be collected approximately every 6 months throughout the lifetime of the device, enrolling a minimum of 500 patients.

Results

The primary endpoint of the study is major system-related complication-free survival at 5 years post-implantation, with a minimum threshold of >79%. The study will also characterize device performance that includes, but is not limited to, freedom from system- or procedure-related complications, performance of antitachycardia pacing, characterization of sensing and detection, inappropriate therapy, shock effectiveness, battery depletion, and system revisions.

Conclusion

The Enlighten Study: the EV-ICD Post-Approval Registry will examine the real-world performance of the post-market EV-ICD system. Additionally, this study will allow for a robust assessment of EV-ICD–related complications, device revisions, and extractions over chronic (>5 years) implant durations.